Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease

NCT06471829 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT06471829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06471829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease
Lead sponsor
H. Lundbeck A/S
Phase
Phase 2
Overall status
Recruiting
Start date
June 19, 2024
Completion date
October 31, 2027
Enrollment
18 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's disease